There has been a steady stream of encouraging data on stem cells for MS. Particularly for certain kinds of MS. A new study adds to this upbeat direction. Good news on stem cells for MS Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study, Journal of Neurology, Neurosurgery, […]
Weekly reads: stem cells for MS, Kimera Labs IND, FDA lawsuit Read More »
So many things have gotten very expensive these days that it got me thinking this past week again about stem cell cost. For this reason, I’ve been running polls asking people what they’ve paid for stem cells and how many therapies they’ve gotten. Before jumping into our weekly reads, check out our informational post on
Weekly reads: stem cell cost, trial death, HSCT for MS, Neuralink Read More »
Totipotency literally means all powerful, but it refers in biology to specific cells. These cells can make every type of cell in the body of an organism plus the extraembryonic tissues needed for development. This includes humans. So if you could reprogram human cells like blood or skin cells into totipotent stem cells, you might
Weekly reads: gene therapy nod, Nature pub ethics, CRISPR LDL Read More »
Today’s post takes a close look at the exosome manufacturer Kimera Labs in the context of the main exosome companies. What are exosomes? Exosomes are microscopic bubbles or vesicles produced by cells. Exosomes contain many cellular substances that are biologically active. Some of these materials may be helpful clinically, while others could pose risks. Clinical outcomes
Review of where Kimera Labs fits into sphere of exosome companies Read More »
Let’s start with a couple of new pieces on in vivo reprogramming. The idea here is to do something like making iPS cells but doing it inside organisms and not quite pushing cells all the way back to pluripotency. Just younger, healthier cells. Why do that? The goal is to achieve a kind of anti-aging
Weekly reads: reprogramming aging, astrocytes, cartilage, ChatGPT Read More »
Let’s start with some stem cell good news on evolving approaches to treat sickle cell disease involving stem cells. Then on another related front things were more concerning. Stem cell good news on sickle cell disease, a complication Sickle Cell Disease News reports Adding Briquilimab Boosts Success of Sickle Cell Stem Cell Transplant. This is a
Weekly reads: stem cell good news, bad news on sickle cell, MS, IPSCs Read More »
Patients regularly reach out and ask me about something called HSCT. “What is HSCT?” and is it proven as a therapy? Often the patients asking about this have multiple sclerosis (MS) or some other autoimmune disease. I’m not a physician so I can’t give medical advice, but as a stem cell biologist here at UC
What is HSCT & its possible roles in MS treatment? Read More »
How promising is the idea of stem cells for MS? I have been working slowly as time permits on a piece more specifically about hematopoietic stem cell transplantation (HSCT) for MS. Two new pieces caught my eye on this topic so I’ll start with those. Stem cells for MS NurOwn Found Safe, Shows Promise in
Weekly reads: stem cells for MS, blood origins, iPSCs Read More »
It’s very challenging to be an academic scientist even under normal circumstances so when a government starts going after researchers for things like supposed irregularities in funding disclosures, it can cause serious problems if not carefully overseen. We’ll start this week’s recommended reads with the feds monitoring such disclosures and even making referrals to the
Weekly reads: Yale scientist suspended, WA AG sues clinic, new pubs Read More »
About 1 million people are living with multiple sclerosis in the U.S. alone with millions of other cases around the world so a huge effort has gone into trying to find new approaches to the disease including stem cells for MS. We’ll start our weekly recommended reads by talking about a new paper on MS
Stem cells for MS & other weekly reads: CRISPR, COVID & a bat cave, Huntington’s Read More »